Allergy and Immunology · Cincinnati, OH
NPI
1093713638
Since 2005
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
4665 E Galbraith Rd Fl 2
Cincinnati, OH, 45236
Phone (513) 931-0775
Medicare paid, 2024
$47K
1,343 services
Medicare patients, 2024
276
Average age 71
Drug cost, 2024
$3.9M
2,505 prescriptions
Company payments, 2025
$121K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan A Bernstein was code 99214 (office e&m - established), 331 times for 211 patients. In total Jonathan A Bernstein billed 1,343 services in 27 codes, and Medicare paid $47K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 331 | 211 | $81.50 | $27K |
| 95165 Treatment - Miscellaneous | Office | 226 | 12 | $9.15 | $2,067 |
| 95117 Treatment - Miscellaneous | Office | 104 | 17 | $6.70 | $697 |
| 94010 Pulmonary Function Testing | Office | 92 | 89 | $16.74 | $1,540 |
| 99204 Office E&M - New | Office | 47 | 47 | $109.86 | $5,163 |
| 99213 Office E&M - Established | Office | 47 | 42 | $61.82 | $2,906 |
| 95012 Pulmonary | Office | 36 | 34 | $12.12 | $436 |
| 99215 Office E&M - Established | Office | 19 | 15 | $98.56 | $1,873 |
| 99205 Office E&M - New | Office | 16 | 16 | $114.72 | $1,836 |
By year: 2022 $42K for 1,086 services; 2023 $44K for 1,170 services; 2024 $47K for 1,343 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan A Bernstein prescribed most often to Medicare patients was Azelastine Hcl, with 239 prescriptions and refills. In total Jonathan A Bernstein wrote 2,505 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azelastine Hcl Generic | 239 | 413 | 95 | $7,473 |
| Fluticasone Propionate Generic | 166 | 335 | 64 | $3,089 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 157 | 197 | 32 | $123K |
| Famotidine Generic | 145 | 281 | 32 | $2,104 |
| Montelukast Sodium Generic | 145 | 316 | 37 | $1,408 |
| Ipratropium Bromide Generic | 87 | 158 | 39 | $3,489 |
| Prednisone Generic | 72 | 97 | 32 | $450 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 67 | 91 | 27 | $2,040 |
| Omeprazole Generic | 66 | 138 | 20 | $630 |
| Symbicort Budesonide/Formoterol Fumarate | 59 | 71 | 13 | $16K |
| Takhzyro Lanadelumab-Flyo | 55 | 55 | Under 11 | $2.1M |
| Spiriva Respimat Tiotropium Bromide | 53 | 93 | 14 | $47K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 52 | 73 | 17 | $8,238 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 49 | 65 | 13 | $6,262 |
| Arnuity Ellipta Fluticasone Furoate | 46 | 68 | Under 11 | $16K |
Brand drugs: 804 claims; generic drugs: 1,701 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan A Bernstein $121K ($101K in general payments such as food, travel and fees and $20K for research) from 26 companies. The largest payer was CSL Behring with $33K.
| Company | Payments | Amount |
|---|---|---|
| CSL Behring CSL.AX | 36 | $33K |
| Novartis Pharmaceuticals Corporation NVS | 24 | $28K |
| Pharming Healthcare, Inc. | 14 | $15K |
| Eli Lilly and Company LLY | 3 | $10K |
| F. Hoffmann-La Roche AG ROG.SW | 3 | $9,197 |
| Abbvie Inc. ABBV | 6 | $8,657 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 11 | $5,690 |
| BioCryst Pharmaceuticals, Inc. BCRX | 5 | $4,453 |
| Genzyme Corporation SNY | 12 | $4,345 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $500 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.